Preparation of scientific reports on pharmacokinetic drug interaction studies

Journal of Clinical Psychopharmacology

Volumn 28, Issue 4, 2008, Pages 369-373

  Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; METHODOLOGY; PHARMACOKINETIC DRUG INTERACTION STUDY MANUSCRIPT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; SCIENTIFIC LITERATURE; DRUG INTERACTION; HUMAN; PHARMACOKINETICS; PUBLISHING; STANDARD;

DRUG INTERACTIONS; GUIDELINES AS TOPIC; HUMANS; MANUSCRIPTS AS TOPIC; PHARMACOKINETICS; PUBLISHING; RESEARCH DESIGN;

EID: 54449098492     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31817e63cd     Document Type: Editorial

References (19)

1. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31:815-832.
2. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol. 2003;43:443-469.
3. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential- towards a consensus. Br J Clin Pharmacol. 2001;52:107-117.
4. Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther. 2007;81:298-304.
5. Huang SM, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. JClin Pharmacol. 2008;48:662-670.
6. Volak LP, Greenblatt DJ, von Moltke LL. In vitro approaches to anticipating clinical drug interactions. In: Li AP, ed. Drug-Drug Interactions in Pharmaceutical Development. Philadelphia, PA: Wiley- Interscience; 2008:31-74.
7. Farkas D, Shader RI, von Moltke LL, et al. Mechanisms and consequences of drug-drug interactions. In: Gad SC, ed. Preclinical Development Handbook: ADME and Biopharmaceutical Properties. Philadelphia, PA: Wiley-Interscience; 2008:879-917.
8. Greenblatt DJ, von Moltke LL. Drug-drug interactions: clinical perspectives. In: Rodrigues AD, ed. Drug-Drug Interactions. 2nd ed. New York, NY: Informa Healthcare; 2008:643-664.
9. Friedman H, Greenblatt DJ, Burstein ES, et al. Population study of triazolam pharmacokinetics. Br JClin Pharmacol. 1986;22:639-642.
10. Greenblatt DJ, Harmatz JS, Friedman H, et al. A large-sample study of diazepam pharmacokinetics. Ther Drug Monit. 1989;11:652-657.
11. Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of Zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol. 2006;46:1469-1480.
12. Pabst G, Jaeger H. Review of methods and criteria for the evaluation of bioequivalence studies. Eur JClin Pharmacol. 1990;38:5-10.
13. Pidgen AW. Statistical aspects of bioequivalence-a review. Xenobiotica. 1992;22:881-893.
14. Steinijans VW, Hartmann M, Huber R, et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol. 1991;29:323-328.
15. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;56:601-607.
16. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. JPharmacol Exp Ther. 1996;276:370-379.
17. Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther. 1998;64:237-247.
18. Granfors MT, Backman JT, Neuvonen M, et al. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther. 2004;75:331-341.
19. Fuhr U. What is the true risk of a pharmacokinetic drug-drug interaction? Eur J Clin Pharmacol. 2007;63:897-899.